FBT

First Trust NYSE Arca Biotechnology Index Fund

Up$149.57
+$1.02
(+0.69%)
As of 1:00:00 AM EDT | 12/13/19  |  Market Closed

FBT Trading Data

Open

$150.09

Low Price

$149

High Price

$151.62

Previous Last Price

$148.55

Bid Size

$0 X 0

Ask Size

$0 X 0

FBT Portfolio Data

AUM

$1,812,632,600

Shares

12,250

PE Ratio

21.14

Price / Book Ratio

4.35

Expense Ratio

0.57

Net Asset Value

$147.97

Volume

Volume

68,500

Avg. Volume (YDT)

161,500

Dollar Volume

$12,288,882

Weekly Avg. Volume

81,400

Monthly Avg. Volume

87,280

Quarterly Avg. Volume

116,273

FBT Fund Description

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July and October to ensure that each component stock continues to represent approximately equal weight in the index.

FBT Chart

FBT Summary

Fund Family

First Trust Portfolios

Tracks This Index

First Trust NYSE Arca Biotechnology Index Fund

Inception Date

2006-06-19

Asset Class

Equity

Asset Class Size

Biotech

FBT Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

FBT Holdings

Top 10 Holdings

Intercept Pharmaceuticals Inc. (ICPT)
5.19%
QIAGEN N.V. (QGEN)
4.12%
Alnylam Pharmaceuticals Inc. (ALNY)
3.97%
Agios Pharmaceuticals Inc. (AGIO)
3.77%
Biogen Inc. (BIIB)
3.76%
Seattle Genetics Inc. (SGEN)
3.61%
Nektar Therapeutics (NKTR)
3.54%
Regeneron Pharmaceuticals Inc. (REGN)
3.52%
Vertex Pharmaceuticals Incorporated (VRTX)
3.5%
Incyte Corporation (INCY)
3.46%

Total FBT Holdings

Total Holdings: 32

Intercept Pharmaceuticals Inc. (ICPT)
5.19%
QIAGEN N.V. (QGEN)
4.12%
Alnylam Pharmaceuticals Inc. (ALNY)
3.97%
Agios Pharmaceuticals Inc. (AGIO)
3.77%
Biogen Inc. (BIIB)
3.76%
Seattle Genetics Inc. (SGEN)
3.61%
Nektar Therapeutics (NKTR)
3.54%
Regeneron Pharmaceuticals Inc. (REGN)
3.52%
Vertex Pharmaceuticals Incorporated (VRTX)
3.5%
Incyte Corporation (INCY)
3.46%
FibroGen Inc. (FGEN)
3.45%
Neurocrine Biosciences Inc. (NBIX)
3.35%
Sarepta Therapeutics Inc. (SRPT)
3.35%
Alkermes Plc (ALKS)
3.27%
Amgen Inc. (AMGN)
3.27%
BioMarin Pharmaceutical Inc. (BMRN)
3.23%
ACADIA Pharmaceuticals Inc. (ACAD)
3.19%
United Therapeutics Corporation (UTHR)
3.19%
Alexion Pharmaceuticals Inc. (ALXN)
3.15%
Ionis Pharmaceuticals Inc. (IONS)
3.13%
Grifols S.A. (ADR) (GRFS)
3.09%
Charles River Laboratories International Inc. (CRL)
3.08%
Bio-Techne Corporation (TECH)
3.05%
Exelixis Inc. (EXEL)
3.04%
Gilead Sciences Inc. (GILD)
2.96%
Illumina Inc. (ILMN)
2.93%
IQVIA Holdings Inc. (IQV)
2.84%
bluebird bio Inc. (BLUE)
2.75%
Ultragenyx Pharmaceutical Inc. (RARE)
2.72%
Exact Sciences Corporation (EXAS)
2.5%
US Dollar ($USD)
0.04%
First Trust Amex Biotech Index Fund ETF (FBT)
0%

FBT Technicals

Alpha

-4.49

Beta

1.45

Leverage

Long

Standard Deviation

8.29

FBT Dividends

Dividend Date

2015-09-23

Latest Dividend

0.02

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

FBT Performance

YTD Return

20.43%

1 Year Return

12.93%

3 Year Return

58.31%

5 Year Return

42.04%

10 Year Return

423.7%

FBT Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.